Physician profile
Manoj K Eapen
NPI 1801892666
$17,203.60
in general payments reported to CMS, 2019-2025
31 companies · $1,840 in 2025
The $1,840 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,313 · 2020: $4,830 · 2021: $216 · 2022: $3,749 · 2023: $667 · 2024: $1,589 · 2025: $1,840.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,096.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,095.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,859.23 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Cardiovascular Systems INC. | $2,324.34 | 2019-2022 | |
| Medtronic Vascular, INC. | $2,152.29 | 2020 | |
| Penumbra, INC. | $1,720.57 | 2019-2020 | |
| Medtronic, INC. | $1,677.46 | 2021-2025 | Aurora Ev-Icd Mri Surescan, Micra, Symplicity G3 |
| Abiomed | $1,666.10 | 2019-2025 | Impella |
| Boston Scientific Corporation | $882.76 | 2019-2022 | |
| Edwards Lifesciences Corporation | $731.34 | 2019-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Amgen INC. | $291.94 | 2021-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $284.89 | 2023-2025 | |
| Pfizer INC. | $281.36 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $263.01 | 2023-2025 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $254.24 | 2023-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $239.38 | 2023-2025 | Verquvo, Winrevair, Capvaxive |
| Atricure, INC. | $204.60 | 2024-2025 | Synergy Ablation System, Atriclip Laa Exclusion System |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $200.93 | 2022-2025 | Farxiga, Wainua |
| Inari Medical, INC. | $196.97 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $161.49 | 2022-2023 | Lifevest |
| Shockwave Medical, INC | $150.44 | 2025 | |
| Philips North America LLC | $149.80 | 2019 | |
| Inspire Medical Systems, INC. | $124.40 | 2023 | Inspire |
| Esperion Therapeutics, INC. | $102.50 | 2023-2024 | Nexletol |
| Novo Nordisk INC | $82.52 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Kestra Medical Technology Services, INC. | $35.61 | 2024 | Assure Wcd |
| Kiniksa Pharmaceuticals International, Plc | $32.91 | 2024 | Arcalyst |
| Bridgebio Pharma, INC. | $30.14 | 2025 | Attruby |
| Baxter Healthcare | $26.02 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Alnylam Pharmaceuticals INC. | $24.31 | 2025 | Amvuttra |
| Scpharmaceuticals INC. | $21.87 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $21.60 | 2024 | |
| Itamar Medical INC | $8.58 | 2023 | Watchpatone |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manoj Eapen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.